Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor

• Egile Nagusiak: Vinod Anera Balakrishna (Egilea), Anitha Police (Egilea), Rakesh Hiremath (Egilea), Anusha Raj (Egilea), Suresh P Sulochana (Egilea), Devaraj V Chandrasekhar (Egilea), Zainuddin Mohd (Egilea), Ravi Kanth Bhamidipati (Egilea), Ramesh Mullangi (Egilea)
• Formatua: Liburua
• Argitaratua: International Association of Physical Chemists (IAPC), 2017-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Ulixertinib (BVD-523) is a novel and selective reversible inhibitor of ERK1/ERK2. In xenograft studies it inhibited tumor growth in BRAF-mutant melanoma and colorectal xenografts as well as KRAS-mutant colorectal and pancreatic models. Ulixertinib is currently in Phase I clinical development for the...